Apomorphine tolerance in Parkinson's disease: Lack of a dose effect

Clinical Neuropharmacology

Volumn 19, Issue 1, 1996, Pages 59-64

  Gancher, Stephen T ^a   Woodward, William R ^a,b   Nutt, John G ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Apomorphine; Parkinson's disease; Pharmacodynamics; Tolerance

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; APOMORPHINE; DOMPERIDONE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; NAXAGOLIDE;

ARTICLE; BOLUS INJECTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG TOLERANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR PERFORMANCE; PARKINSON DISEASE; PRIORITY JOURNAL; VOMITING;

EID: 0030067273     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199619010-00004     Document Type: Article

References (18)

1. Grandas F, Obeso JA. Motor response following repeated apomorphine administration is reduced in Parkinson's disease. Clin Neuropharmacol 1989;12:14-22.
2. Hughes AJ, Lees AJ, Stern GM. The motor response to sequential apomorphine in parkinsonian fluctuations. J Neurol Neurosurg Psychiatry 1991;54:358-60.
3. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-3.
4. Gancher ST, Nutt JG, Woodward WR. Time course of tolerance to apomorphine in parkinsonism. Clin Pharmacol Ther 1992;52:504-10.
5. Parkes JD. Domperidone and Parkinson's disease. Clin Neuropharmacol 1986;9:511-32.
6. Gancher ST, Woodward WR, Boucher B, Nutt JG. Peripheral pharmacokinetics of apomorphine in humans. Ann Neural 1989;26:232-8.
7. James MA, Papouchado M, Jones JV. Attenuation of nitrate effect during an intermittent treatment regimen and the time course of nitrate tolerance. Eur Heart J 1991;12:1266-72.
8. Zimrin D, Reichek N, Bogin KT, et al. Antianginal effects of intravenous nitroglycerin over 24 hours. Circulation 1988;77:1376-84.
9. Ambre JJ, Belknap SM, Nelson J, Ruo TI, Shin SG, Atkinson AJ. Acute tolerance to cocaine in humans. Clin Pharmacol Ther 1988;44:1-8.
10. Boisse NR, Periana RM, Guarino JJ, Kruger HS, Samoriski GM. Pharmacologic characterization of acute chlordiazepoxide dependence in the rat. J Pharmacol Exp Ther 1986;239:775-83.
11. Winkler JD, Weiss B. Reversal of supersensitive apomorphine-induced rotational behavior in mice by continuous exposure to apomorphine. J Pharmacol Exp Ther 1986;238:242-7.
12. Fernandes M, Kluwe S, Coper H. Quantitative assessment of tolerance to and dependence on morphine in mice. Naunyn Schmiedebergs Arch Pharmacol 1977;297:53-60.
13. Luquin MR, Laguna J, Herrero MT, Obeso JA. Behavioral tolerance to repeated apomorphine administration in parkinsonian monkeys. J Neural Sci 1993;114:40-4.
14. Grandas F, Gancher S, Lera G, et al. Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease. Neurology 1992;42:1287-90.
15. Cedarbaum JM, Silvestri M, Kutt H. Sustained enteral administration of levodopa increases and interrupted infusion decreases levodopa dose requirements. Neurology 1990;40:995-7.
16. Nutt JG, Carter JH, Woodward W, Hammerstad JP, Gancher ST. Does tolerance develop to levodopa? Comparison of 2- and 21-h levodopa infusions. Mov Disord 1993;8:139-43.
17. Vaamonde J, Luquin MR, Obeso JA. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease. Clin Neuropharmacol 1989;12:271-84.
18. 2-receptor agonist administered as a long-acting formulation. Mov Disord 1990;5:298-303.